Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2785–2808 of 4,253 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Differential Diagnosis, Diagnostic Accuracy
Interventions: AI Diagnostic System (AIMD.1); Diagnostic Test
Lead sponsor: Magic Health Inc. (d.b.a. Nolla Health); Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma
Interventions: SM17, Placebo; Biological · Other
Lead sponsor: SinoMab BioScience Ltd; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Type 2 Diabetes
Interventions: Colesevelam, Placebo, Diet, Metformin; Drug · Other · Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 35 Years to 70 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chronic Insomnia
Interventions: Ramelteon, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 55 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 72
States / cities: Alabaster, Alabama • Huntsville, Alabama • Phoenix, Arizona + 69 more

Conditions: Generalized Anxiety Disorder
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 33
States / cities: Anaheim, California • Arcadia, California • Irvine, California + 30 more

Conditions: Diabetes, Diabetes Mellitus, Type 1, Type1diabetes, Diabetes Mellitus
Interventions: YG1699, Dapagliflozin; Drug
Lead sponsor: Youngene Therapeutics Inc., Ltd.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Osteoporosis
Interventions: ALX1-11 50 mcg, placebo, ALX1-11 75mcg, ALX1-11; Drug
Lead sponsor: Shire; Industry
Eligibility: 50 Years to 75 Years · Female only
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 1997
U.S. locations: 15
States / cities: Peoria, Arizona • Loma Linda, California • Mill Valley, California + 12 more

Conditions: Persistent Atrial Fibrillation
Interventions: FARAPULSE™ Pulsed Field Ablation System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 33
States / cities: Mobile, Alabama • Jonesboro, Arkansas • Los Angeles, California + 29 more

Conditions: Analgesia, Postoperative Pain, Block
Interventions: Ropivacaine 0.5% Injectable Solution; Drug
Lead sponsor: Bruce Ben-David; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Bipolar I Depression
Interventions: Armodafinil, Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 42
States / cities: Birmingham, Alabama • Escondido, California • Lafayette, California + 35 more

Conditions: Tuberous Sclerosis Complex
Interventions: Early Vigabatrin, Delayed Vigabatrin (Placebo); Drug
Lead sponsor: Martina Bebin; Other
Eligibility: 1 Day to 6 Months
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 10 more

Conditions: Obesity
Interventions: IHBG-10, Placebo; Dietary Supplement
Lead sponsor: Avera McKennan Hospital & University Health Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Allergic Conjunctivitis
Interventions: K-Lens (generic name not established) and Ketotifen, Placebo Lens; Device
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 8 Years and older
Enrollment: 310 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: Gardena, California • North Andover, Massachusetts • Memphis, Tennessee

Conditions: Type 2 Diabetes
Interventions: UMS Strategy, SMS Texting Reminders; Other
Lead sponsor: Northwestern University; Other
Eligibility: 30 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Covid19
Interventions: TQ Formula/Tab; Drug
Lead sponsor: Novatek Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: San Diego, California • Hialeah, Florida • Houston, Texas

Conditions: Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD)
Interventions: PLS240, Placebo, Open-Label Extension PLS240; Drug
Lead sponsor: Pathalys Pharma; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 49
States / cities: Pine Bluff, Arkansas • Anaheim, California • Beverly Hills, California + 41 more

Conditions: Dental Caries
Interventions: Nano Silver Fluoride / NSF; Device
Lead sponsor: A.T. Still University of Health Sciences; Other
Eligibility: 6 Years to 10 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Mesa, Arizona

Conditions: Influenza
Interventions: cH15/3, cH4/3, cH5/1N1, cH8/1N1, Saline; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Neuroblastoma, Cancer
Interventions: Biopsy, Next Generation Sequencing, Tumor Scans, Bone marrow Tests, Physical Exam, Eye Exam, Labs, Pregnancy Test, Interviews, ECG, Echocardiogram, Ribociclib, Ceritinib; Procedure · Genetic · Other + 2 more
Lead sponsor: Yael P Mosse; Other
Eligibility: 1 Year to 21 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: NMO Spectrum Disorder, Spasticity, Muscle
Interventions: Nabiximols, Placebo; Drug
Lead sponsor: Michael, Levy M.D.,Ph.D.; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acne Vulgaris
Interventions: GDC 268 Lotion, Clindamycin Phosphate Lotion 1%, GDC Vehicle Lotion; Drug
Lead sponsor: Balmoral Medical company; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 1,236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 34
States / cities: Fort Smith, Arkansas • Rogers, Arkansas • Fountain Valley, California + 31 more

Conditions: Healthy Volunteers
Interventions: TAK-925, TAK-925 Placebo, Modafinil, Modafinil Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Batoclimab 340 mg SC weekly, Placebo; Drug
Lead sponsor: Immunovant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 21
States / cities: Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 17 more

Conditions: Plaque Psoriasis
Interventions: TAK-279, Placebo, Apremilast; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 66
States / cities: Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 54 more

Search by objective public record fields.

Evaluation of One-Shot Vision Differential Diagnosis (OSVDE) and Multi-Step Conversational Non-Inferiority (MSCNE) in AI Medical Interviewing

A Phase 1 Study of Single and Multiple Intravenous Doses of SM17 in Healthy Subjects

The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics

Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease

An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes

A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis

Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System

Volume vs Concentration: Quadratus Lumborum Blocks With High Volume/Low Concentration or Low Volume/ High Concentration in Nephrectomies

Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex

Randomized Study to Evaluate the Effect of an Investigational Product on Weight Loss and Body Composition

Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers

Promoting the Universal Medication Schedule Via Mobile and EHR Technologies

To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1

A Study to Evaluate the Cariostatic Efficacy of Nano Silver Fluoride (NSF) vs. Silver Diamine Fluoride (SDF) in Children

Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates

Next Generation Personalized Neuroblastoma Therapy

A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders

Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-925 Study in Sleep-Deprived Healthy Adults

To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period